At a glance
The TESTS phase 3 trial provides a substantial disease-specific test. A May 2025 correction updated survival and immunological data without changing the overall interpretation that a mortality reduction was not demonstrated.
Identity & scope
The cited research concerns the defined thymosin alpha-1 study drug. A research-category label such as immune signalling describes the topic, not proof that a supplied peptide improves immunity.
What the research shows
- The corrected TESTS analysis did not show a significant reduction in 28-day all-cause mortality.
- The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76 to 1.24.
Critical interpretation
Why a larger follow-up matters
The earlier ETASS result illustrates the fragility of a conclusion that changes with the statistical comparison. A numerical difference, a borderline survival test and an interval that includes no effect should not be compressed into an unqualified positive result. The larger, double-blind TESTS study then provides a more substantial test of the mortality hypothesis in its defined population. [3] [1]
Interpret uncertainty rather than reverse the null result
A confidence interval containing no effect does not prove the true effect is exactly zero. It constrains the effects compatible with the trial under its assumptions. Conversely, a favourable age or diabetes subgroup cannot establish a treatment indication merely because the overall result was negative. That would need a prespecified, independently replicated comparison with appropriate attention to interaction and multiplicity. [1]
Publication corrections belong in the evidence chain
The TESTS correction is an analysis update, not another trial or a retraction. It matters because a reader extracting an older abstract may enter superseded values into a review. Our interpretation is that version control is part of evidence quality: record which corrected publication supplied each estimate and retain its linked notice. A study count should exclude such notices from the number of independent clinical experiments. [1] [2]
Limitations & uncertainties
- A null sepsis result does not answer every possible indication, but cannot support a general immune-benefit claim.
- Subgroup suggestions do not override the overall primary result.
- The trial does not establish equivalence or safety of a commercial research vial.
Open research questions
- Which prespecified patient populations, if any, show a reproducible benefit in independent trials?
- Are future analyses based on the corrected dataset and clearly registered outcomes?
Selected papers & source records
Download bibliography1. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial (opens in a new tab)
Wu J, Pei F, Zhou L, et al.; TESTS study collaborator group (2025). BMJ. DOI: 10.1136/bmj-2024-082583 (opens in a new tab) · PMID 39814420
- Design & population
- Multicentre phase 3 double-blind placebo-controlled study, with 1106 adults randomised and 1089 in the modified intention-to-treat analysis.
- What the study found
- Corrected results show no significant 28-day mortality reduction: hazard ratio 0.97 (95% CI 0.76 to 1.24), P=0.82.
- Limits on interpretation
- Use the corrected publisher version. The overall result does not support an immune-enhancement or sepsis-survival claim.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. Correction: The efficacy and safety of thymosin α1 for sepsis (TESTS) (opens in a new tab)
BMJ (2025). BMJ. DOI: 10.1136/bmj.r1098 (opens in a new tab) · PMID 40447307
- Design & population
- Publisher correction to the TESTS trial, published 30 May 2025; not an additional clinical study.
- What the study found
- Updated survival analyses after obtaining follow-up data for nine participants and corrected lymphocyte data for 35 participants.
- Limits on interpretation
- The correction changes estimates, not the overall conclusion of no clear mortality benefit. Older cached abstracts can contain superseded statistics.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (opens in a new tab)
Wu J, Zhou L, Liu J, et al. (2013). Critical Care. DOI: 10.1186/cc11932 (opens in a new tab) · PMID 23327199
- Design & population
- Six-centre single-blind randomised trial in 361 patients with severe sepsis.
- What the study found
- Reported lower 28-day mortality numerically; the unstratified comparison was not significant and the confidence interval for relative risk included no effect. A log-rank analysis was borderline significant.
- Limits on interpretation
- Analysis-dependent result in an earlier, less fully blinded trial. It should not be presented as definitive mortality reduction.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.
Earlier ETASS trial, larger TESTS trial and its publisher correction. Corrected publisher results retained where a cached PubMed abstract is outdated. Not an all-indication or pooled meta-analysis.
Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.
Recorded search terms
- 39814420 thymosin alpha1 sepsis randomized placebo mortality
- "TESTS" "e082583" correction 2025
- "The efficacy and safety of thymosin" "Wu" 2025 e082583
- thymosin alpha1 ETASS trial 2013 severe sepsis randomized PubMed
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Thymosin Alpha-1: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/thymosin-alpha-1.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.